Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,464.79 -4.51 (-0.08%) Dow
38,961.64 -150.52 (-0.38%) Nasdaq
17,751.52 +33.87 (+0.19%) Bitcoin USD
61,752.18 +457.09 (+0.75%) CMC Crypto 200
1,278.18 -5.60 (-0.44%)
ITCI Jun 2024 90.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 04:02PM EDT. Market open.
| Previous close | 20.80 |
| Open | N/A |
| Bid | 23.30 |
| Ask | 25.70 |
| Strike | 90.00 |
| Expiry date | 2024-06-21 |
| Day's range | 20.80 - 20.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.